Follistatin-344 — the myostatin-pathway glycoprotein, explained
Follistatin is a secreted glycoprotein first isolated in 1987 for its ability to inhibit pituitary follicle-stimulating hormone (FSH) release, and subsequently re-characterized as a high-affinity binding protein for the TGF-β superfamily ligands activin and myostatin (GDF-8). Three natural isoforms arise from alternative splicing and post-translational processing: FS-288, FS-315, and FS-344. Vivaprime supplies the FS-344 isoform specifically. This primer covers the molecule, the isoform distinction, the myostatin pathway, the published research on skeletal-muscle mass regulation, and research-context framing for this compound.
The three isoforms. The human FST gene encodes a primary translation product that can be processed into multiple mature forms. FS-315 (315 residues of mature protein after signal-peptide cleavage) is the longest naturally secreted form and carries a C-terminal heparin-binding domain that anchors it to cell-surface glycosaminoglycans. FS-288 (288 residues) is the shorter form generated by alternative splicing, lacking the C-terminal acidic region and thus circulating freely in serum without cell-surface anchoring. FS-344 (344 residues) is a less-characterized intermediate form that retains the C-terminal acidic region and has emerged in the research literature on circulating follistatin-activin dynamics. Functionally, all three isoforms bind activin and myostatin with high affinity; they differ primarily in tissue distribution and cell-surface binding behavior. Molecular weight of FS-344 is approximately 38-40 kDa including N-linked glycosylation (two N-glycosylation sites).
The myostatin pathway. Myostatin (GDF-8) is a TGF-β-superfamily ligand secreted primarily by skeletal muscle that acts as a negative regulator of muscle mass. Myostatin binds type II activin receptors (ActRIIA and ActRIIB) on muscle-cell membranes, recruiting type I receptors (ALK4/ALK5) and triggering SMAD2/3 phosphorylation, which downregulates protein synthesis and activates atrophy pathways. Naturally occurring myostatin loss-of-function mutations produce the 'double-muscled' phenotype in Belgian Blue cattle, Texel sheep, and rare human cases. Follistatin sequesters myostatin before it engages ActRIIB, effectively disinhibiting muscle growth. This is the central research rationale for follistatin in skeletal-muscle research.
Published literature — primary sources. The foundational isolation paper is Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA. 1987;84(23):8282-8286 (doi: 10.1073/pnas.84.23.8282). The myostatin-binding characterization is in Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel K. Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol. 2004;270(1):19-30 (doi: 10.1016/j.ydbio.2004.01.046). The structural-biology paper on receptor competition is Cash JN, Angerman EB, Kattamuri C, Nolan K, Zhao H, Sidis Y, Keutmann HT, Thompson TB. Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of interaction. J Biol Chem. 2012;287(2):1043-1053 (doi: 10.1074/jbc.M111.270801). For the broader muscle-mass regulation context: Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98(16):9306-9311 (doi: 10.1073/pnas.151270098).
Research applications. Follistatin (in all three isoforms, with FS-288 and FS-344 being the most-used in research contexts) has been studied in (1) skeletal-muscle mass regulation — the central application, typically in rodent models where follistatin administration produces measurable increases in muscle mass and fiber diameter; (2) myopathy research — preclinical rodent and non-human primate studies examined follistatin as a research tool, with AAV-mediated follistatin gene-transfer work reaching early human trials; (3) FSH-axis research — the original discovered activity, still referenced in reproductive-research contexts; (4) tissue-remodeling and tissue-regeneration research — follistatin's activin-binding activity is relevant to fibrosis and regeneration models.
What FS-344 adds to the catalog. Much of the peer-reviewed follistatin research in skeletal-muscle contexts has used FS-288 and FS-315 isoforms. FS-344 is less-characterized but has emerged as the most-referenced isoform in research on circulating follistatin-activin dynamics — its longer sequence relative to FS-288 and its retention of the C-terminal acidic region give it distinct pharmacokinetic and tissue-distribution properties. FS-344 is the isoform supplied by Vivaprime's producer, and the FS-344 vs. FS-288 distinction is a meaningful research-design consideration: protocols should reference the specific isoform used, not follistatin generally.
Administration routes and dose ranges. Follistatin is a secreted glycoprotein, not a small peptide, and research administration has been exclusively subcutaneous or intramuscular (not oral — no oral bioavailability). Published rodent studies have used a wide range of doses (100-500 μg/kg) administered daily or every-other-day over multi-week protocols. Human data is limited to the gene-therapy-based studies mentioned above; direct-injection human data is essentially absent from the peer-reviewed literature. Vivaprime supplies FS-344 at 1 mg/mL concentration (3 mg per 3 mL pen) — a research-context concentration appropriate for multi-site in-vitro work and rodent-scale research protocols.
Storage and handling. Follistatin is a ~40 kDa glycoprotein, and protein-stability considerations dominate over peptide-stability considerations. Refrigerate 2-8 °C. Do not freeze — freeze-thaw cycles can cause aggregation and loss of activity. Avoid vigorous agitation during handling. Protect from light. The prefilled-pen format controls for the freeze-thaw and aggregation risks that historically made follistatin a difficult reagent to work with at research scale. In-use stability is shorter than for small peptides — refer to the pen label for specifics.
What the COA should say. A batch-specific COA for follistatin FS-344 should include (1) identity by mass spectrometry — for a glycosylated ~40 kDa protein, the measured mass will reflect the glycan heterogeneity, so tolerance is wider than for small peptides; SDS-PAGE migration is commonly reported as a complementary identity check, (2) purity by SDS-PAGE and analytical size-exclusion chromatography, (3) endotoxin by LAL in EU/mg — critical for recombinant proteins produced in E. coli or other microbial systems, (4) bioactivity by activin-neutralization or myostatin-neutralization cell-based assay — optional but valuable for confirming the protein folds correctly and retains biological activity. The production source (mammalian cell line, E. coli, or yeast) should be disclosed since glycosylation status differs dramatically.
Research-use only. Vivaprime supplies follistatin-344 as research reference material for qualified researchers engaged in in-vitro and research-context work. Follistatin has not been approved by the FDA for any therapeutic indication. Systemic administration of follistatin or agents that modulate myostatin signaling is an area of active research with incomplete long-term safety characterization — researchers working in this area should consider potential effects on non-muscle tissues where myostatin-family signaling is physiologically relevant (cardiac tissue, tendon, adipose). Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Purchasers affirm the research-use agreement at checkout. Related primers: [IGF-1 LR3](/blog/igf-1-lr3-research-primer), [ipamorelin and CJC-1295](/blog/ipamorelin-cjc-1295-research-primer).